AbstractBackgroundAlthough guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.ObjectiveTo bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.DesignA...

AbstractIntroductionFIRE-3 compared 1st-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type mCRC patients. The Consensus Molecular Subgroups (CMS) are grouping CRC samples according to their gene-signature in four different subtypes. Relevance of CMS for the treatment of mCRC has yet to be defined.MethodsIn this...

SummarySelf-learning healthcare systems are becoming a reality. As boundaries between research and healthcare delivery become increasingly blurred, there is an emerging opportunity to accelerate learning through the cyclical integration and analysis of patient phenotype, treatment and clinical outcome. Opportunities already exist to save money through...